US11013734 — Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation
Method of Use · Assigned to Forma Therapeutics Inc · Expires 2039-05-16 · 13y remaining
What this patent protects
Methods are described for treating patients with AML or MDS who have an IDH-1 mutation by administering an IDH-1 inhibitor alone or with azacitidine or cytarabine.
USPTO Abstract
Methods of treating patients diagnosed with AML or MDS harboring mutant IDH-1 include detecting an IDH1 mutation and the therapeutic administration of an inhibitor of a mutant IDH-1 as a single agent, or in combination with azacitidine (AZA) or cytarabine.
Drugs covered by this patent
- Rezlidhia (OLUTASIDENIB) · Rigel Pharms
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-3495 |
— | Rezlidhia |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.